PUBLISHER: Grand View Research | PRODUCT CODE: 1842111
PUBLISHER: Grand View Research | PRODUCT CODE: 1842111
The Brain cancer diagnostics market size was valued at USD 1.61 billion in 2024 and is expected to reach USD 3.06 billion by 2033, growing at a CAGR of 7.60% from 2025 to 2033. The market growth is driven by the rising global incidence of primary and metastatic brain tumors, coupled with the need for early and accurate detection to guide complex treatment decisions.
Growing adoption of advanced imaging modalities (MRI, PET-MRI), integration of molecular profiling into WHO and NCCN guidelines, and the increasing role of AI-enabled platforms are fueling market growth. In addition, expanding reimbursement for DNA methylation profiling and heightened patient advocacy initiatives are accelerating access, standardization, and demand for innovative diagnostic solutions.
The global brain cancer diagnostics industry represents a high-value, high-need opportunity at the intersection of oncology and advanced diagnostics. Although brain cancers account for just ~2% of all cancers, they rank among the most burdensome malignancies worldwide, driving the fourth highest number of years of life lost across cancers. Treatment costs are exceptionally high, and patients typically undergo lifelong surveillance and follow-up scans. Importantly, until recently, brain tumors were the leading cause of cancer-related death among pediatric and young adult patients, underscoring the unmet medical need.
From a market perspective, this unique disease burden translates into sustained demand for diagnostics. The clinical reality is that therapeutic innovation in brain tumors has lagged behind other cancers; as a result, patient management is disproportionately dependent on accurate, repeated, and advanced diagnostics.
Global Brain Cancer Diagnostics Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the brain cancer diagnostics market report based on cancer type, product, technique, end use, and region: